Patents by Inventor Judith A. Abraham

Judith A. Abraham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
    Patent number: 7476506
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: January 13, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
    Publication number: 20080008711
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Application
    Filed: April 18, 2007
    Publication date: January 10, 2008
    Inventors: Siew Schleyer, Anne Jefferson, Judith Abraham, W. Kavanaugh
  • Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
    Publication number: 20070148691
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Application
    Filed: February 9, 2007
    Publication date: June 28, 2007
    Inventors: Siew Schleyer, Anne Jefferson, Judith Abraham, W. Kavanaugh
  • Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
    Patent number: 7198899
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 3, 2007
    Assignee: Chiron Corporation
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Recombinant fibroblast growth factor analogs
    Patent number: 7186526
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 6, 2007
    Assignee: Scios, Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Recombinant fibroblast growth factor analogs
    Publication number: 20050227329
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: June 13, 2005
    Publication date: October 13, 2005
    Inventors: John Fiddes, Judith Abraham, Andrew Protter
  • Vascular endothelial growth factor dimers
    Publication number: 20050119165
    Abstract: This invention concerns novel vascular endothelial growth factor (VEGF) dimers, compositions containing such dimers, processes for making such dimers, and methods for the treatment of various diseases by administering such dimers or compositions.
    Type: Application
    Filed: August 13, 2004
    Publication date: June 2, 2005
    Applicant: Scios, Inc.
    Inventors: Rodney Jue, Ute Schellenberger, Peter Stathis, Peter Adriaenssens, Judith Abraham, Patricia Baldwin, N. Pollitt
  • Vascular endothelial growth factor variants
    Patent number: 6887848
    Abstract: The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: May 3, 2005
    Assignee: Scios, Inc.
    Inventors: N. Stephen Pollitt, Judith A. Abraham
  • Vascular endothelial growth factor dimers
    Publication number: 20040241800
    Abstract: This invention concerns novel vascular endothelial growth factor (VEGF) dimers, compositions containing such dimers, processes for making such dimers, and methods for the treatment of various diseases by administering such dimers or compositions.
    Type: Application
    Filed: December 31, 2003
    Publication date: December 2, 2004
    Inventors: Rodney Alan Jue, Ute Schellenberger, Peter A. Stathis, Peter Isadore Adriaenssens, Judith A. Abraham, Patricia Ann Baldwin, N. Stephen Pollitt
  • Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
    Publication number: 20040005622
    Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
    Type: Application
    Filed: June 3, 2003
    Publication date: January 8, 2004
    Applicant: Chiron Corporation
    Inventors: Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh
  • Vascular endothelial growth factor variants
    Publication number: 20030096754
    Abstract: The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.
    Type: Application
    Filed: October 10, 2002
    Publication date: May 22, 2003
    Inventors: N. Stephen Pollitt, Judith A. Abraham
  • Recombinant fibroblast growth factors
    Publication number: 20030040042
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: July 9, 2001
    Publication date: February 27, 2003
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Vascular endothelial growth factor variants
    Patent number: 6475796
    Abstract: The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: November 5, 2002
    Assignee: Scios, Inc.
    Inventors: N. Stephen Pollitt, Judith A. Abraham
  • Human basic fibroblast growth factor analog
    Patent number: 6294359
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: September 25, 2001
    Assignee: Scios Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Heparin binding mitogen with homology to epidermal growth factor (EGF)
    Patent number: 6235884
    Abstract: Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: May 22, 2001
    Assignees: Scios Nova, Inc., The Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Judith A. Abraham, Shigeki Higashiyama, Gail E. Besner
  • Human basic fibroblast growth factor analog
    Patent number: 5859208
    Abstract: A human basic fibroblast growth factor (FGF) protein analog wherein the cysteine at positions 78 and 96 is replaced by serine, and said analog exhibits the biological activity of native, human basic FGF.The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: February 12, 1990
    Date of Patent: January 12, 1999
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew A. Protter
  • Heparin binding mitogen with homology to epidermal growth factor (EGF)
    Patent number: 5811393
    Abstract: Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.
    Type: Grant
    Filed: June 15, 1993
    Date of Patent: September 22, 1998
    Assignees: The Childrens Medical Center Corp., Scios Nova, Inc.
    Inventors: Michael Klagsbrun, Judith A. Abraham, Shigeki Higashiyama, Gail E. Besner
  • Recombinant human basic fibroblast growth factor
    Patent number: 5604293
    Abstract: The DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting wound healing and related tissue repair.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: February 18, 1997
    Assignee: Scios Inc.
    Inventors: John C. Fiddes, Judith A. Abraham
  • Methods of producing recombinant fibroblast growth factors
    Patent number: 5514566
    Abstract: Disclosed herein are the DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF). Expression of these sequences results in practical amounts of proteins useful in effecting wound healing.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: May 7, 1996
    Assignee: SCIOS Nova Inc.
    Inventors: John C. Fiddes, Judith A. Abraham
  • DNA encoding human recombinant basic fibroblast growth factor
    Patent number: 5439818
    Abstract: Disclosed herein are the DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF). Expression of these sequences results in practical amounts of proteins useful in effecting wound healing.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: August 8, 1995
    Assignee: Scios Nova Inc.
    Inventors: John C. Fiddes, Judith A. Abraham